<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE nitf PUBLIC "-//IPTC//NITF DTD 3.0//EN" "nitf-3-0.dtd"><nitf baselang="EN-US"><head><meta content="CITE" name="_lnbillview"/><meta content="00001" name="_lnminrev"/><meta content="June 2, 2017" name="_eoptdate"/><meta content="13:46:55 EDT" name="_eopttime"/><meta content="DOCUMENT_TOKEN_PLACEHOLDER" name="documentToken"/><docdata><doc-id id-string="5NP7-B8K1-DXKH-N3JH" regsrc="lexisnexis.com"/><date.issue norm="20170602T000000Z"/>2017-06-02</docdata><pubdata unit-of-measure="word" item-length="802" position.section="STOCK" name=" News Bites - Nordic: Sweden"/></head><body><body.head><hedline><hl1>ExpreS2ion Biotech underperforms 94% of the market June 02, 2017 17:20 CEST</hl1></hedline></body.head><body.content/></body></nitf>